LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Home・Aktien・Amarin Corp PLC ADR

Amarin Corp PLC ADR

Geschlossen

0.56 -1.75

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.56

Max

0.57

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 1.5M
Verkäufe	11M 67M
EPS	0.01
Gewinnspanne	2.252
EBITDA	13M 237K

Empfehlungen
By TipRanks
Empfehlungen	Sell
12-Monats-Prognose	+72.41 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-18M 237M
Vorheriger Eröffnungskurs	2.31
Vorheriger Schlusskurs	0.56

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

0.575 / 0.6039 Unterstützung & Widerstand

Amarin Corp PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2024, 23:57 UTC

Heiße Aktien

Stocks to Watch: Netflix, MGP Ingredients, Bausch Health

17. Okt. 2024, 22:35 UTC

Akquisitionen, Fusionen, Übernahmen

SLB to Sell Interest in Palliser Block in Canada

17. Okt. 2024, 21:33 UTC

Ergebnisse

Wichtige Markttreiber

Intuitive Surgical Shares Rise 6% After 3Q Earnings, Revenue Beat

17. Okt. 2024, 20:56 UTC

Ergebnisse

Intuitive Surgical Posts 3Q Revenue Growth

17. Okt. 2024, 23:51 UTC

Market Talk

BHP Unlikely to Quickly Approach Anglo American Again, Says Bull -- Market Talk

17. Okt. 2024, 23:22 UTC

Top News

Amex Earnings Will Test Stock's Rally. Revenue Is the Focus. -- Barrons.com

17. Okt. 2024, 23:14 UTC

Top News

Ergebnisse

Netflix Subscriber Growth Slows Amid Revenue Gains -- 4th Update

17. Okt. 2024, 22:56 UTC

Market Talk

Santos's Balance Sheet Risks to Ease From Here -- Market Talk

17. Okt. 2024, 22:52 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Santos's Upcoming Investor Day Likely Positive -- Market Talk

17. Okt. 2024, 22:32 UTC

Market Talk

De Grey Runs Into Delay on Hemi Permitting, But Approval Likely -- Market Talk

17. Okt. 2024, 22:23 UTC

Market Talk

Nike Outlook Revised on Unclear Outcome of Turnaround Strategy -- Market Talk

17. Okt. 2024, 22:13 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

17. Okt. 2024, 22:13 UTC

Market Talk

Ergebnisse

Netflix Isn't Interested in Bundling With Other Streaming Services -- Market Talk

17. Okt. 2024, 21:57 UTC

Top News

Ergebnisse

Netflix Subscriber Growth Slows Amid Revenue Gains -- 3rd Update

17. Okt. 2024, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

SLB: Palliser Block Consists of Oil and Gas Wells, Surface Facilities, a Pipeline Network and Certain Oil and Gas Development Rights >SLB

17. Okt. 2024, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

SLB: Transaction Is Expected to Close Late in the 4Q >SLB

17. Okt. 2024, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

SLB: Announces Definitive Agreement to Sell Its Interests in Palliser Block

17. Okt. 2024, 21:32 UTC

Market Talk

Ergebnisse

Netflix's Release Schedule Should be 'Largely Back to Normal' in 2025 -- Market Talk

17. Okt. 2024, 21:25 UTC

Top News

Google Executive Overseeing Search and Advertising Leaves Role -- 2nd Update

17. Okt. 2024, 21:21 UTC

Market Talk

Ergebnisse

Netflix Says It Will Double Revenue from Advertising in FY25 -- Market Talk

17. Okt. 2024, 21:18 UTC

Ergebnisse

Wichtige Markttreiber

Intuitive Surgical Shares Rise 6% After 3Q Earnings, Rev Beat

17. Okt. 2024, 21:10 UTC

Top News

Ergebnisse

Lucid Stock Tumbles 18%. EV Maker Plans Huge Share Sale, Sees Wider Losses. -- Barrons.com

17. Okt. 2024, 21:03 UTC

Akquisitionen, Fusionen, Übernahmen

CSX, Canadian Pacific Kansas City, Genesee & Wyoming: Surface Transportation Board Approves CSX, CPKC Respective Applications Regarding Acquisition of Rail Lines Operated by G&W's Meridian & Bigbee Railroad

17. Okt. 2024, 20:55 UTC

Ergebnisse

Netflix Clobbers Third-Quarter Estimates, Guides Above Views -- IBD

17. Okt. 2024, 20:55 UTC

Ergebnisse

Netflix Stock Jumps on a Strong Outlook for Profit Margin. Prices Are Going Up Across the World. -- Barrons.com

17. Okt. 2024, 20:50 UTC

Ergebnisse

Netflix Stock Jumps on a Strong Outlook for Profit Margin. Prices Are Growing Up Across the World. -- Barrons.com

17. Okt. 2024, 20:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

17. Okt. 2024, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

17. Okt. 2024, 20:50 UTC

Market Talk

Ergebnisse

Basic Materials Roundup: Market Talk

17. Okt. 2024, 20:49 UTC

Top News

Ergebnisse

Netflix Subscriber Growth Slows Amid Revenue Gains -- 2nd Update

Peer-Vergleich

Kursveränderung

Amarin Corp PLC ADR Prognose

Kursziel

By TipRanks

72.41% Vorteil

12-Monats-Prognose

Durchschnitt 1 USD 72.41%

Hoch 1 USD

Tief 1 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amarin Corp PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Amarin Corp PLC ADR – Dist abgegeben haben.

Technischer Score

By Trading Central

0.575 / 0.6039Unterstützung & Widerstand

All events are bearish.

Recent bullish events outweigh bearish events.

There are no events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.